Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in...
14 insider purchases on record · latest filing 2025-03-13.
Insiders have also filed 104 sale transactions at SLDB.